---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-111979"
form_type: "8-K"
ticker: "FBIO"
cik: "0001429260"
company_name: "Fortress Biotech, Inc."
filed_at: "2025-11-14T23:59:59+00:00"
generated_at: "2026-05-16T19:49:47.352396+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Fortress Biotech Q3 net revenue up 20.5% to $17.6M; net income $3.7M vs prior loss

## Summary
- Net revenue $17.6M (Q3 2025) vs $14.6M (Q3 2024), driven by dermatology product sales.
- Net income attributable to common stockholders $3.7M ($0.13 basic EPS) vs net loss of $15.0M in Q3 2024.
- Cash and equivalents $86.2M as of Sep 30, 2025, up from $57.3M at Dec 31, 2024.
- Checkpoint sale to Sun Pharma closed May 2025; Fortress received ~$28M upfront plus up to $4.8M CVR and 2.5% royalty on UNLOXCYT sales.
- Dotinurad Phase 3 trials dosed Oct 2025; Crystalys raised $205M Series A; Urica (Fortress sub) holds equity and 3% royalty.

## SEC filing metadata
- accession: 0001104659-25-111979
- form_type: 8-K
- ticker: FBIO
- cik: 0001429260
- company_name: Fortress Biotech, Inc.
- filed_at: 2025-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1429260/000110465925111979/0001104659-25-111979-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1429260/000110465925111979/fbio-20251114x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-111979
- JSON: https://secwatch.observer/filing/0001104659-25-111979.json
- Plain text: https://secwatch.observer/filing/0001104659-25-111979.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.